Our investment philosophy is founded in four main principles
Activating success for those companies and entrepreneurs we support
Providing Added-value expertise beyond capital investment through our own extensive drug discovery, scientific and managerial expertise
Committing to Ongoing investment with those entrepreneurs and companies with whom we work
Offering Opportunities for the future for portfolio companies to enter into strategic partnerships with the Boehringer Ingelheim Research and Development organization

Ultimately, our goal is to add value to those companies we invest in, delivering success for them and generating revenues to finance further new investment to benefit patients.

The Boehringer Ingelheim Venture Fund intends to invest in groundbreaking therapeutic approaches and technologies that have the potential to advance patient care and meet unmet medical needs.

No. Our primary aim is to search for significant enhancements in patient care through innovative and pioneering science. These include but are not limited to:

• Address "undrugable" targets, e.g. targets that are poorly amendable to either current NCEs or NBEs
• Next generation vaccines, e.g. T-Cell vaccines
• Next generation NBEs, e.g. cancer immunotherapeutics
• Regenerative medicine
• New platforms for Targets and Biomarkers identification

All applications for funding that support our primary aim will be welcomed.

In addition, we recognise that innovation is not restricted by geography and welcome applications from entrepreneurs worldwide.

The Boehringer Ingelheim Venture Fund will be seeking to provide initial investments in seed or series A funding.

Opening investments of up to €2 million per venture will be made at the early stage with subsequent staged investments made to align with each venture’s progress, up to a total of €10-15 million per venture over its life.

The Boehringer Ingelheim Venture Fund intends to play an active role in the companies it supports, not only in either a Board or Board Observer capacity, but also through the value-added expertise it will be able to offer which will be crucial to improving the clinical and commercial outcome of the venture.

The management of conflict of interest is extremely important, both to protect the interests of the entrepreneurs and Boehringer Ingelheim. The highest levels of confidentiality and secure ethical walls are established to ensure that the interests of all parties are protected while maximising the expertise of both parties.

In the first instance, please complete the template in the Applications for Funding section of this website and send to venture@boehringer-ingelheim.com . For additional questions please contact our office in Ingelheim, Germany (tel: +49 6132 77-8740).

Initial evaluation of applications is based on the business plan and supporting materials (technical and financial) provided by the applicant. Further review with the investment team will be subsequent to this and will take the form of more detailed presentations and a robust due diligence process.